Open Access

Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases

  • Authors:
    • Kazuhiko Kasuya
    • Minako Suzuki
    • Yuichi Nagakawa
    • Yoshiaki Suzuki
    • Satoru Kikuchi
    • Bunso Kyo
    • Takaaki Matsudo
    • Takao Itoi
    • Akihiko Tsuchida
    • Tatsuya Aoki
  • View Affiliations

  • Published online on: December 6, 2011     https://doi.org/10.3892/etm.2011.409
  • Pages: 347-350
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In addition to the use of chemotherapeutic agents for the prevention of multiple liver metastases from colorectal cancer, the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, is often used, and its effectiveness has been established. By contrast, it has been reported that the use of bevacizumab prior to or following surgery delays wound healing or liver regeneration. In this study, we investigated whether the administration of bevacizumab following hepatectomy inhibits remnant liver regeneration or the growth of remnant metastases. Mice were partially hepatectomized (31% of the liver was removed), transplanted with the murine colorectal cancer cell line, CT26, in the remnant lobe, and intraperitoneally injected with bevacizumab (4 mg/kg) for a total of 6 times. Serum VEGF levels were measured on day 1 following surgery, and each lobe of the liver was weighed on day 14. Serum VEGF levels in non-hepatectomized, tumor-bearing mice exceeded those in their non-tumor-bearing counterparts; however, the administration of bevacizumab did not reduce the serum VEGF levels. The volume of the liver lobe of the hepatectomized, CT26‑transplanted and non-CT26-transplanted mice was 1,349.6 and 735.5 mg, respectively, indicating rapid growth of the CT26 transplant (p=0.023). The volume of the CT26-transplanted lobe of the bevacizumab-administered mice was 1,379.0 mg, which was not significantly different from that (1,349.6 mg) of the non-bevacizumab-administered mice. The volume of the remnant lobe of the bevacizumab-administered mice was 1,051.0 mg, which did not significantly differ from that (957.3 mg) of the non-bevacizumab-administered mice. The administration of bevacizumab following hepatectomy did not delay remnant liver regeneration, and did not suppress the growth of metastases in the remnant lobes or remnant liver regeneration.
View Figures
View References

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kasuya K, Suzuki M, Nagakawa Y, Suzuki Y, Kikuchi S, Kyo B, Matsudo T, Itoi T, Tsuchida A, Aoki T, Aoki T, et al: Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases. Exp Ther Med 3: 347-350, 2012
APA
Kasuya, K., Suzuki, M., Nagakawa, Y., Suzuki, Y., Kikuchi, S., Kyo, B. ... Aoki, T. (2012). Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases. Experimental and Therapeutic Medicine, 3, 347-350. https://doi.org/10.3892/etm.2011.409
MLA
Kasuya, K., Suzuki, M., Nagakawa, Y., Suzuki, Y., Kikuchi, S., Kyo, B., Matsudo, T., Itoi, T., Tsuchida, A., Aoki, T."Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases". Experimental and Therapeutic Medicine 3.2 (2012): 347-350.
Chicago
Kasuya, K., Suzuki, M., Nagakawa, Y., Suzuki, Y., Kikuchi, S., Kyo, B., Matsudo, T., Itoi, T., Tsuchida, A., Aoki, T."Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases". Experimental and Therapeutic Medicine 3, no. 2 (2012): 347-350. https://doi.org/10.3892/etm.2011.409